Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Castle Biosciences Inc
(NQ:
CSTL
)
31.47
+0.94 (+3.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Castle Biosciences Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma
October 31, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
October 27, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone
October 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
October 24, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
October 20, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2
October 19, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management
October 13, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting
October 11, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
October 10, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma
September 23, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference
September 21, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day
September 20, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association
September 13, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Participate in Upcoming Investor Conferences
September 01, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Host Investor Day on Sept. 20, 2022
August 24, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Reports Second Quarter 2022 Results
August 08, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus
August 04, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8
July 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma
July 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma
July 20, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Honored with a 2022 Arizona Top Workplace Award
July 18, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative
June 23, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022
June 22, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Support for OHSU’s War on Melanoma™
June 20, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma
June 14, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present at the JMP Securities Life Sciences Conference
June 08, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award
May 27, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
May 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
May 24, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.